Cary Pfeffer - Nov 12, 2021 Form 4 Insider Report for Jounce Therapeutics, Inc. (JNCE)

Role
Director
Signature
/s/ Cary Pfeffer
Stock symbol
JNCE
Transactions as of
Nov 12, 2021
Transactions value $
$0
Form type
4
Date filed
11/16/2021, 06:54 PM
Previous filing
Sep 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNCE Common Stock Sale $0 0 $0.00* 0 Nov 12, 2021 See Footnote F1, F2, F3
holding JNCE Common Stock 0 Nov 12, 2021 See Footnote F4
holding JNCE Common Stock 50.5K Nov 12, 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 12, 2021, Third Rock Ventures III, L.P. ("TRV III") sold 1,900,000 shares of Common Stock of the Issuer at an average price per share of $8.38.
F2 After the above transaction, TRV III owned 1,148,780 shares of Common Stock of the Issuer.
F3 The Reporting Person is a partner of Third Rock Ventures GP III, L.P., which is the general partner of TRV III. The Reporting Person disclaims beneficial ownership over the shares held by TRV III, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
F4 Third Rock Ventures II, L.P. ("TRV II") directly holds 2,697,829 shares of the Issuer's Common Stock. The Reporting Person is a partner of Third Rock Ventures GP II, L.P., which is the general partner of TRV II. The Reporting Person disclaims beneficial ownership over the shares held by TRV II, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.